Introduction
Acute venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients [1] . Cancer patients have a 4 to 6 fold higher risk of developing incident VTE compared to matched non-cancer patients [2, 3] , they have a higher risk of recurrent VTE [4, 5] , and development of VTE in cancer patients is associated with higher mortality [6] [7] [8] . The management of acute VTE in cancer patients may be challenging because they have an increased risk of developing major bleeding during anticoagulation therapy [4] . The frequency of vena caval filter (VCF) use in the management of patients with acute VTE has expanded exponentially, with one study showing a 20-fold increase between 1979-1999 [9] . The use of VCFs has emerged as a particularly common therapeutic modality in patients with cancer in the United States although the clinical benefit in this setting remains controversial [10, 11] .
The American College of Chest Physicians 2012 guidelines recommend against the use of VCFs in patients with acute VTE except in patients who have a contraindication to therapeutic anticoagulation, such as patients with active bleeding or patients who require surgery [12] . Nevertheless recent studies have documented great variation in use of VCFs among hospitals in the United States. In a populationbased study from Worcester Massachusetts, VCFs were placed in 13% of 1547 patients hospitalized for acute VTE, but by consensus of three experts, the use of VCF was appropriate in only 51% of the cases [13] . Another large retrospective study found a striking variation in the frequency of VCF placement in patients hospitalized for acute VTE, with a range of from 0 to 39%. This study found that cancer patients had 70% higher odds of VCF use compared to patients without cancer [14] .
Although VCF placement in cancer patients appears to be common, there have been no studies that have determined the factors associated with more frequent use of VCFs in patients with cancer. The objective of this study was to determine the clinical, demographic and hospital characteristics associated with VCF use in cancer patients. We hypothesized the use of VCFs would be higher in those patients with a contraindication to anticoagulation as well as in those with cancers that were perceived to have a high bleeding risk.
Methods
This was retrospective observational study that was designed to determine factors associated with VCF use in patients who required hospitalization specifically for acute lower extremity deep-vein-thrombosis (DVT) or pulmonary embolism (PE) and had cancer. We restricted the analysis to patients admitted to a hospital in California between Jan 1, 2005 and Dec 31, 2009. This study was approved by the California Health and Welfare Agency Committee for the Protection of Human Subjects, and the University of California, Davis Institutional Review Board.
Databases
The California Patient Discharge Database (PDD) contains information about all patients hospitalized in the state, except patients admitted to one of 14 Federal hospitals (12 Veterans Affairs hospitals and two military hospitals). Serial records from a single person can be linked using an encrypted form of the social-security number, called the record linkage number (RLN) [15, 16] . All PDD records include demographic information, insurance status (e.g. self-pay, Medicare, insurance, etc.), a principal medical diagnosis, up to 24 additional 'secondary' diagnoses, and a principal and up to 20 secondary procedures coded using International Classification of Diseases, 9th Revision, Clinical Modification codes (ICD-9-CM). Since 1996 all medical diagnoses in the PDD required a present-on-admission (POA) indicator. The database also includes a hospital identifier with the ability to link to hospital characteristics (e.g. public, academic, for-profit, etc.) and location (rural vs. urban).
Acute -VTE
All cases admitted with a principal diagnosis of either acute DVT in the lower extremity or acute PE between Jan 1, 2005 and Dec 31, 2009 were first identified (see Supplemental Appendix for ICD-9-CM codes). Cases diagnosed with hospital-acquired acute VTE only were identified by the presence of a secondary diagnosis code for acute VTE coupled with a POA indicator of no (POA = N). Hospital-acquired VTE cases were excluded to ensure that VTE occurred prior to filter placement. For each linked record, we selected only the first hospitalization for acute-VTE during the study period.
Cancer Cases
Cases were categorized as having cancer based on the presence of a cancer diagnosis code (see Appendix) at the time of admission or within a 6 month time period prior to the index hospitalization. Cases with unknown cancer primary site were excluded from the cohort. Cancer type was categorized by "perceived" bleeding risk (high bleed risk-brain, high bleed risk-acute leukemia, moderate bleed risk-urinary and kidney, and low bleed risk-all others). The within-hospital frequency of VCF placement in cases with and without cancer was also compared.
Vena Cava Filter Use
All cases hospitalized for acute VTE with cancer that had a VCF placed were identified by procedure code 38.7 (interruption of the vena cava). Although this procedure code is also used for vena cava plication, ligation or other interruption, these other procedures are rarely performed [17, 18] . All of the cases with acute VTE that had a VCF placed any time prior to Jan 1, 2005 (back to Jan, 1991) were excluded. The frequency of VCF use was calculated as the number of hospitalizations that included VCF placement divided by the corresponding total number of hospitalizations for acute VTE.
Hospitals
Optimally the frequency of VCF use should be compared only among hospitals that admitted at least a minimal number of VTE cases. We targeted hospitals that admitted a minimum of 55 or more acute VTE hospitalizations over the 6-year study period in our previous analysis of non-cancer cases, the current study required the same but there was no minimal number of cancer cases. This cut-off of 55 hospitalizations was chosen in order ensure that there were a sufficient number of "opportunities" for VCF placement to guarantee that the 95% confidence limits on the calculated frequency of VCF use was not wider than 10%, assuming that the average frequency of VCF use was 15%. The within hospital VCF use correlation between cancer and noncancer patients was restricted to hospitals with at least 55 acute VTE cases, and 15 or more acute VTE cancer patients (223 hospitals) as well in order to improve the reliability of this calculation.
Active Bleeding
Cases with bleeding were identified using ATRIA Study identified set of ICD-9-CM codes [19, 20] . Cases were classified as having intracranial bleeding, gastrointestinal bleeding, or "other" bleeding. Hematuria alone and epistaxis were included only if the patient also received a blood transfusion. Bleeding was categorized as either present at the time of admission or that developed during the hospital stay using the POA flag (Y/W = on admission, N/U = during the hospitalization). Having active bleeding was considered a contraindication to anticoagulation.
Surgery
Major operating room procedures were identified using a set of ICD-9-CM codes used by the Centers for Medicare and Medicaid Services. This list was modified by excluding relatively minor operating room procedures such as cosmetic surgery, and endoscopic procedures commonly performed outside of the operating room, such as upper gastrointestinal endoscopy, colonoscopy and cystoscopy. Vascular procedures commonly performed in conjunction with either thrombolysis, venous stenting or placements of a VCF were analyzed separately.
Major surgery was defined as undergoing a major operation during the index hospitalization. Prior surgery was defined as undergoing surgery within 7 days prior to the index hospitalization. Insertion of VCF was not counted as a major surgery. Undergoing surgery was considered a contraindication to anticoagulation.
Co-morbidity and Severity-of-illness
Chronic co-morbid conditions (up to 26) were defined using the Elixhauser co-morbidity software (see Supplemental Appendix) [21, 22] . Cancer was not counted as a co-morbidity in this analysis. Cases with cancer were classified as having metastatic cancer (ICD-9-CM 196.0-199.9) or non-metastatic cancer (ICD-9-CM 140.0-195.9, 200.0-209.9). Proprietary software from 3M™ (APR-DRG grouper, V-24) was applied to every record to determine the severity-of-illness (SOI) at the time of admission, which was classified as mild, moderate, major or extreme [23] .
Statistical Analysis
Categorical data were analyzed using Chi-square testing. Univariate models were used to determine differences in VCF use between groups. Multivariable logistic regression modeling was used to model potential predictive factors for VCF use, which included age, sex, metastatic disease, perceived bleeding risk of cancer type and other clinical characteristics, race/ethnicity and insurance status as socioeconomic factors, and hospital-specific characteristics (size by number of beds, location and type). Kaiser Foundation hospitals were compared to other private and teaching hospitals because they uniquely reflect the care provided by a large, highly penetrant and vertically integrated health maintenance organization.
Analyses were performed using SAS® (9.3 and 9.4) and a two-sided p-value less than 0.05 was considered statistically significant.
Results
A total of 87,150 cases were identified with a principal diagnosis code of VTE, either pulmonary embolism or lower extremity deep venous thromboembolism. We excluded cases with no active cancer (N = 71,996) or cancer with unknown primary site (N = 1090). We also excluded cases from hospitals with less than 55 acute VTE cases (N = 64). Our final cohort included a total of 14,000 patients admitted with acute VTE and cancer, but without any prior record of having a VCF placed (Fig. 1) . Bleeding occurred in 5.6% of all cases and a major surgery was noted in 2.6%. A VCF was inserted in 19.6% of the cancer cases. The frequency of VCF use varied widely between hospitals with a range of 0% to 52% among 223 hospitals that had more than 55 acute VTE hospitalizations and 15 or more of these in patients with cancer.
There were 7,194 filters placed amongst 64,348 acute VTE cases that did not have cancer (11.2%). Fig. 2 shows the correlation between the frequency of filter use in the cancer and non-cancer cases. For most hospitals, the use of VCFs was greater in cancer patients with acute VTE compared to non-cancer patients. There was a high correlation in the frequency of VCF use in non-cancer and cancer patients within a hospital (r = 0.71, R 2 = 0.51).
The frequency distribution of VCF use, and proportions of patients with VCF placement that had bleeding and surgery, by cancer type is shown is Fig. 3 . Cases with brain cancer had the highest frequency of VCF use (43%) whereas it was much lower in patients with lymphoma (13%), leukemia (13%), breast (12%) and lip/oral cancer (8%). Of note, in the cases with brain cancer and VTE that had a VCF placed, only 9% had bleeding and 9% surgery (some had both). As shown in Fig. 3 , the proportion of patients within each tumor type with contraindication to anticoagulation (bleeding or surgery) also greatly varied.
The bivariate frequency of VCF use based on clinical/demographic, socioeconomic, and hospital-characteristics is shown in Table 1 . There was no significant difference in VCF use based on race/ethnicity, insurance status or type of facility. Among these cases with acute VTE, the frequency of VCF placement was higher in the cases with active bleeding (47.0%), brain cancer (43.0%), major surgery (58.4%), cases with metastatic cancer (22.0%) and cases with a greater number of comorbid conditions or increasing severity of illness at the time of admission. The use of VCFs was low in hospitals with fewer than 100 beds (7.5%) but similar in hospitals with 100-200 beds (17.4%) and those with over 200 beds (20.8%). Use of VCFs was only 14.1% in Kaiser hospitals compared to 19% in teaching hospitals and 21.1% in private hospitals. Use in rural hospitals was quite low, 6.5% compared to urban hospitals (20.2%). The multivariable logistic regression model analyzing predictors of VCF use is shown in Table 2 . The strongest clinical predictors of VCF use were having brain cancer (OR = 4.6, 95% CI: 3.7-5.6), major surgery during the hospitalization (OR = 4.9, 95% CI: 3.9-6.1), bleeding at the time of admission (OR = 2.7, 95% CI: 2.1-3.5), bleeding during the hospitalization (OR = 2.7, 95% CI: 1.9-3.9); major severity-of-illness (OR = 1.9, 95%CI: 1.5-2.4), extreme severity-of-illness (OR = 1.8, 95%CI: 1.4-2.4) and metastatic cancer (OR = 1.5, 95%CI: 1.3-1.6). There was no significant difference in the odds of VCF use when comparing acute leukemia or moderate perceived bleeding risk-bladder and kidney cancers to low perceived bleeding risk cancers.
Differences by hospital characteristics found on univariable analysis were confirmed in the adjusted multivariable model. Smaller and rural hospitals were less likely to place VCF in patients with cancer and acute VTE: fewer than 100 licensed beds (OR = 0.4; 95%CI 0.3-0.5; 100-199 licensed beds (OR = 0.9, 95%CI: 0.8-1.0); and rural location versus urban (OR = 0.4; 95%CI: 0.3-0.5). Private hospitals had significantly greater odds of using a VCF compared to non-teaching Kaiser Foundation hospitals. There was no significant difference in the odds of VCF use when profit and not-for-profit hospitals were compared. This logistic model had a c-statistic of 0.702.
Discussion
In a previous analysis we reported that cancer patients with acute VTE were more likely to have VCF placement compared to non-cancer patients with acute VTE. The major findings of the present study was the wide variation in frequency of VCF use in cancer patients among California hospitals with significant variation depending on the underlying type, metastatic status, and perceived bleed risk of cancer. The frequency of VCF use in cancer patients also differed depending on hospital and clinical characteristics.
In a previous study, the frequency of VCF placement for all patients with acute VTE varied among 263 California hospitals from 0 to 39%. In the present study, we found an even wider variation in the frequency of VCF use in the cancer patients with acute VTE, from 0-52%. Even after adjusting for important factors that might influence the decision to use a VCF, such as bleeding, undergoing surgery, metastases, severity-ofillness, and the number of chronic comorbidities, hospital characteristics were still significantly predictive of VCF use. Admission to a larger, urban and private hospital was associated with greater odds of having a vena caval filter placed. There was also a strong correlation between VCF insertion between cancer and non-cancer patients. This finding suggests that local culture and practice pattern within a hospital affects the use of VCFs. We also speculate that larger private and teaching hospitals may have greater availability of specialists who are skilled in placing VCFs.
The variation in the frequency of VCF placement between cancer types was quite striking, with a very high percentage of cases with brain cancer receiving a VCF, but also frequent use in patients with melanoma and cancer involving the pancreas, female genital tract, colon and urinary tract. However, variable proportions of cases had a clear contraindication for anticoagulation (surgery, active bleeding), despite the high frequency of VCF placement (Fig. 3) . In certain malignancies such as lip/oral and urinary tract, the use of VCFs occurred primarily in those patients undergoing surgery or having active bleeding. However, in other cancers including melanoma, leukemia and brain, VCF placement occurred despite the lack of a clear contraindication to anticoagulation. We hypothesized that part of this variation would be due to a perceived higher risk of bleeding in certain cancer types. Indeed in the adjusted model, having brain cancer was associated with an over 4-fold increased odds of VCF placement. However, having other malignancies often perceived to be associated with higher risk of bleeding such as acute leukemia, bladder and kidney cancer were not significant predictors of VCF placement when adjusted for other covariables. The high rate of VCF placement in melanoma patients was also unexpected, but may be due to a perception that melanoma has a high bleeding risk as a highly vascular malignancy and/or the presence of brain metastases.
Literature on the use of VCFs in patients with brain cancer is limited and inconclusive. In this study, we found that almost half of all brain cancer patients had a VCF placed but only 9 % of these patients had active bleeding and 9 % had major surgery at the time of the index hospitalization or prior 7 days. The high frequency of VCF placement in these patients, despite lack of contraindication to anticoagulation in most, may reflect an overall perception that brain tumors have a higher propensity for intracranial hemorrhage while on anticoagulation. While brain tumors are highly vascular, retrospective studies have suggested the actual risk of intracranial bleeding while on anticoagulation in patients with primary brain tumors is not significantly increased [24] [25] [26] . Several studies have also revealed high rates of complications with VCF use in brain tumor patients [27, 28] . One study found that in 42 patients treated with VCFs, 62% developed complications including recurrent PE and DVT, filter thrombosis and post-thrombophlebitis syndrome. Interesting, none of the patients who received both anticoagulation and VCF had hemorrhagic complications in this report [29] . Despite the overall evidence showing a low rate of intracranial hemorrhage and a high risk of complications related to VCF use, the present study reveals VCFs are frequently used in brain cancer patients. The use of VCFs to treat VTE in patients, both in those with cancer and without cancer, continues to be controversial. A few single center studies have found that VCFs are safe and highly effective in preventing PE-related deaths in patients with both hematological and solid tumors [11, 30] . However, other studies found increased rates of VCF-related complications in cancer patients including new vena caval thrombosis, retroperitoneal hemorrhage, recurrent VTE and mal-deployed filters, and have questioned the benefit of VCF placement in patients with advanced malignancy [10, 11, 26, 31] . Several studies have also reported that in patients with stage III and IV malignant disease, VCF placement conferred no survival benefit compared to treatment with anticoagulation therapy [31, 32] . The cost-effectiveness of VCFs in cancer patients has also been questioned [33, 34] .
Despite uncertain benefit, cancer patients hospitalized with acute VTE are almost two times more likely to have a VCF placed in comparison to non-cancer patients [14] . The clinical variables most strongly associated with VCF placement in cancer patients were active bleeding, undergoing a major operation, presence of metastatic disease, greater severity-of-illness at the time of admission, and presence of comorbidities. However, overall only 21% of those who had a VCF placed had active bleeding or underwent major surgery. Therefore, only a minority of the cancer patients with VCF had a clear contraindication to anticoagulation.
There are a number of limitations to this observational study. There was minimal information on cancer stage (other than metastatic cancer) or cancer therapy. Future studies may determine the effect of these clinical variables on the frequency of VCF placement. There was not reliable data on whether retrievable VCFs were used, and if so whether the filter was retrieved. While it is possible that hospitals that place VCFs in a large proportion of cancer patients with acute VTE do actually remove the VCF within a short period of time, current literature suggests that only a small proportion of retrievable VCFs are actually retrieved [35, 36] . Due to the retrospective nature of the study, it is possible that more patients may have had a contraindication to anticoagulation than observed. While we could not identify the specific clinical indication for placement of each VCF, we did adjust for contraindications to anticoagulation, such as bleeding and undergoing surgery during the hospitalization. While we could not directly determine whether bleeding occurred prior to filter placement, we included both those with bleeding on admission and during the hospitalization in our study cohort. This may mean that even fewer patients actually had active bleeding and a true contraindication to anticoagulation requiring filter placement when initially diagnosed with VTE. We could not identify specific attending physicians or their specialty. There may be as much between-physician variation in VCF use within each hospital as there is variation between hospitals. Thus, the observed degree of variation in VCF use among hospitals may underestimate even larger variations among physician-groups both within and between hospitals.
In conclusion, we observed large variation between hospitals and cancer types in the frequency of VCF use in patients with cancer. Most patients with cancer that had VCF placement did not have clear contraindications to anticoagulation. Further studies are needed to determine if VCF use improves outcomes in cancer patients hospitalized for acute VTE.
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